- Dec 1, 2022
NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT
(GEM21menos65) (Isatuximab-VRD + ASCT) - (VRD extended + ASCT plus ERI) - (Isatuximab-VID + ASCT). ERI=Early Rescue Intervention...
213
- Dec 1, 2022
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Carfilzomib,...
141
- Dec 1, 2022
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma This is a phase II study to determine the...
108
- Dec 1, 2022
NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients
BOREALIS Trial - CMRG 010 NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients Study of...
150
- Dec 1, 2022
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
NCT05354557: Phase 2 - Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant...
88
- Dec 10, 2021
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM
IFM2021_03 NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients...
118